0.20% -0.27

アフターアワーズ： 132.16

Novartis Ag Adr (NVS)

概要ニュース株価時系列オプションチェーンディスカッション予測株式分割株の配当実績

Novartis Ag Adr (NVS) 最新ニュース

05:41 AM

CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035 by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players - GlobeNewswire Inc.

05:41 AM

Nov 29, 2025

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts - Sahm

Nov 20, 2025

Nov 19, 2025

Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Finviz

Nov 19, 2025

Nov 17, 2025

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring - Sahm

Nov 17, 2025

Nov 15, 2025

Net margin % of Novartis AG Sponsored ADR – HAM:NOTA - TradingView

Nov 15, 2025

Nov 13, 2025

Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz

Nov 13, 2025

Nov 06, 2025

Novartis Issues $6 Billion in Debt Securities to Bolster Financial Strategy - The Globe and Mail

Nov 06, 2025

Nov 05, 2025

Stocks Generating Improved Relative Strength: Novartis ADR - Investor's Business Daily

Nov 05, 2025

Oct 29, 2025

Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar

Oct 29, 2025

Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com India

Oct 29, 2025

Oct 28, 2025

Novartis completes acquisition of Tourmaline Bio - Novartis

Oct 28, 2025

'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours - Sahm

Oct 28, 2025

Novartis announces expiration of Tourmaline Bio tender offer - Novartis

Oct 28, 2025

Oct 27, 2025

Stocks Rally on US-China Preliminary Trade Agreement - Barchart.com

Oct 27, 2025

Avidity Biosciences Soars After $72 Per Share Novartis Takeover - Sahm

Oct 27, 2025

Market movers: Qualcomm, Avidity Biosciences, Lululemon, Keurig Dr Pepper… - Proactive financial news

Oct 27, 2025

Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news

Oct 27, 2025

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal - Sahm

Oct 27, 2025

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 27, 2025

Oct 26, 2025

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline - Novartis

Oct 26, 2025

Oct 24, 2025

Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock - Sahm

Oct 24, 2025

Oct 22, 2025

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain - Sahm

Oct 22, 2025

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer - Novartis

Oct 22, 2025

Oct 20, 2025

Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail

Oct 20, 2025

Oct 17, 2025

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm

Oct 17, 2025

Oct 16, 2025

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm

Oct 16, 2025

Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm

Oct 16, 2025

MRK

$99.72

1.16%

NVO

$47.86

0.27%

AMGN

$329.89

3.07%

GILD

$121.22

0.98%

PFE

$26.03

1.28%

Novartis Ag Adr (NVS)

Novartis Ag Adr (NVS) 最新ニュース

CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035 by Target Antigens, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players - GlobeNewswire Inc.

TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029 - Finviz

Why Novartis Stock Topped the Market Today - sharewise.com

NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth - Finviz

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts - Sahm

Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Finviz

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring - Sahm

Net margin % of Novartis AG Sponsored ADR – HAM:NOTA - TradingView

Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz

Novartis Issues $6 Billion in Debt Securities to Bolster Financial Strategy - The Globe and Mail

Stocks Generating Improved Relative Strength: Novartis ADR - Investor's Business Daily

Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar

Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com India

Novartis completes acquisition of Tourmaline Bio - Novartis

'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours - Sahm

Novartis announces expiration of Tourmaline Bio tender offer - Novartis

Stocks Rally on US-China Preliminary Trade Agreement - Barchart.com

Avidity Biosciences Soars After $72 Per Share Novartis Takeover - Sahm

Market movers: Qualcomm, Avidity Biosciences, Lululemon, Keurig Dr Pepper… - Proactive financial news

Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal - Sahm

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline - Novartis

Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock - Sahm

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain - Sahm

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer - Novartis

Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm

Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm

NVSに似た銘柄